Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp

Citizens Jmp cut shares of Allakos (NASDAQ:ALLKFree Report) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports.

Allakos Price Performance

NASDAQ ALLK opened at $0.25 on Monday. The business has a fifty day moving average price of $1.02 and a two-hundred day moving average price of $0.90. The stock has a market capitalization of $22.69 million, a PE ratio of -0.13 and a beta of 0.86. Allakos has a fifty-two week low of $0.23 and a fifty-two week high of $1.69.

Allakos (NASDAQ:ALLKGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. As a group, sell-side analysts expect that Allakos will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Allakos

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in shares of Allakos by 14.6% during the third quarter. FMR LLC now owns 5,370,247 shares of the company’s stock worth $3,508,000 after buying an additional 685,623 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Allakos by 8.9% during the 3rd quarter. Geode Capital Management LLC now owns 988,171 shares of the company’s stock valued at $646,000 after acquiring an additional 80,763 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Allakos in the 3rd quarter worth about $1,143,000. GSA Capital Partners LLP increased its holdings in Allakos by 11.9% in the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock worth $519,000 after purchasing an additional 84,750 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Allakos in the second quarter valued at about $55,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Allakos Company Profile

(Get Free Report)

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.

Featured Stories

Analyst Recommendations for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.